Literature DB >> 31179049

Pulmonary artery denervation: a novel treatment modality for pulmonary hypertension.

Trixie Le1, Christian Makar1, Philip Morway1, Nir Hoftman1, Soban Umar1.   

Abstract

Entities:  

Year:  2019        PMID： 31179049      PMCID： PMC6531721          DOI： 10.21037/jtd.2019.02.93

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  22 in total

1.  Usefulness of beta-blocker therapy and outcomes in patients with pulmonary arterial hypertension.

Authors:  Petsy Pui-Sze So; Ross A Davies; George Chandy; Duncan Stewart; Rob S B Beanlands; Haissam Haddad; Carolyn Pugliese; Lisa M Mielniczuk
Journal:  Am J Cardiol       Date:  2012-03-03       Impact factor: 2.778

2.  β-blocker therapy is not associated with adverse outcomes in patients with pulmonary arterial hypertension: a propensity score analysis.

Authors:  Thenappan Thenappan; Samit S Roy; Sue Duval; Cherylanne Glassner-Kolmin; Mardi Gomberg-Maitland
Journal:  Circ Heart Fail       Date:  2014-10-02       Impact factor: 8.790

3.  Treatment of group I pulmonary arterial hypertension with carvedilol is safe.

Authors:  Daniel Grinnan; Harm-Jan Bogaard; John Grizzard; Benjamin Van Tassell; Antonio Abbate; Christine DeWilde; Anna Priday; Norbert F Voelkel
Journal:  Am J Respir Crit Care Med       Date:  2014-06-15       Impact factor: 21.405

4.  Spontaneous ventricular fibrillation in right ventricular failure secondary to chronic pulmonary hypertension.

Authors:  Soban Umar; Jong-Hwan Lee; Enno de Lange; Andrea Iorga; Rod Partow-Navid; Aneesh Bapat; Arnoud van der Laarse; Rajeev Saggar; Rajan Saggar; Dirk L Ypey; Hrayr S Karagueuzian; Mansoureh Eghbali
Journal:  Circ Arrhythm Electrophysiol       Date:  2011-12-22

5.  Pulmonary artery denervation to treat pulmonary arterial hypertension: the single-center, prospective, first-in-man PADN-1 study (first-in-man pulmonary artery denervation for treatment of pulmonary artery hypertension).

Authors:  Shao-Liang Chen; Feng-Fu Zhang; Jing Xu; Du-Jiang Xie; Ling Zhou; Thach Nguyen; Gregg W Stone
Journal:  J Am Coll Cardiol       Date:  2013-07-10       Impact factor: 24.094

6.  Comparative effects of losartan and nifedipine therapy on exercise capacity, Doppler echocardiographic parameters and endothelin levels in patients with secondary pulmonary hypertension.

Authors:  Serife Savaş Bozbaş; Hüseyin Bozbaş; Asli Atar; Gaye Ulubay; Füsun Oner Eyüboğlu
Journal:  Anadolu Kardiyol Derg       Date:  2010-02

7.  Cervical ganglion block attenuates the progression of pulmonary hypertension via nitric oxide and arginase pathways.

Authors:  Sungwon Na; Ok Soo Kim; Sungwoo Ryoo; Tae Dong Kweon; Yong Seon Choi; Hyo Sup Shim; Young Jun Oh
Journal:  Hypertension       Date:  2013-12-09       Impact factor: 10.190

8.  Percutaneous pulmonary artery denervation completely abolishes experimental pulmonary arterial hypertension in vivo.

Authors:  Shao-Liang Chen; Yao-Jun Zhang; Lin Zhou; Du-Jiang Xie; Feng-Fu Zhang; Hai-Bo Jia; Sally S Wong; Tak W Kwan
Journal:  EuroIntervention       Date:  2013-06-22       Impact factor: 6.534

9.  Chronic carvedilol treatment partially reverses the right ventricular failure transcriptional profile in experimental pulmonary hypertension.

Authors:  Jennifer I Drake; Jose Gomez-Arroyo; Catherine I Dumur; Donatas Kraskauskas; Ramesh Natarajan; Harm J Bogaard; Paul Fawcett; Norbert F Voelkel
Journal:  Physiol Genomics       Date:  2013-04-30       Impact factor: 3.107

10.  Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension.

Authors:  Frances S de Man; Ly Tu; M Louis Handoko; Silvia Rain; Gerrina Ruiter; Charlène François; Ingrid Schalij; Peter Dorfmüller; Gérald Simonneau; Elie Fadel; Frederic Perros; Anco Boonstra; Piet E Postmus; Jolanda van der Velden; Anton Vonk-Noordegraaf; Marc Humbert; Saadia Eddahibi; Christophe Guignabert
Journal:  Am J Respir Crit Care Med       Date:  2012-08-02       Impact factor: 21.405
View more
  3 in total

1.  Mechanosensitive channel Piezo1 is required for pulmonary artery smooth muscle cell proliferation.

Authors:  Jiyuan Chen; Marisela Rodriguez; Jinrui Miao; Jing Liao; Pritesh P Jain; Manjia Zhao; Tengteng Zhao; Aleksandra Babicheva; Ziyi Wang; Sophia Parmisano; Ryan Powers; Moreen Matti; Cole Paquin; Zahra Soroureddin; John Y-J Shyy; Patricia A Thistlethwaite; Ayako Makino; Jian Wang; Jason X-J Yuan
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2022-03-23       Impact factor: 6.011

Review 2.  ACE2 (Angiotensin-Converting Enzyme 2) in Cardiopulmonary Diseases: Ramifications for the Control of SARS-CoV-2.

Authors:  Ravindra K Sharma; Bruce R Stevens; Alexander G Obukhov; Maria B Grant; Gavin Y Oudit; Qiuhong Li; Elaine M Richards; Carl J Pepine; Mohan K Raizada
Journal:  Hypertension       Date:  2020-08-12       Impact factor: 10.190

Review 3.  The progress of pulmonary artery denervation.

Authors:  Yonghui Xie; Na Liu; Zhenghui Xiao; Fang Yang; Yunhong Zeng; Zhou Yang; Yuanxi Xia; Zhi Chen; Yunbin Xiao
Journal:  Cardiol J       Date:  2021-01-13       Impact factor: 3.487
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.